US public-private push to accelerate cancer vaccine development

NCI director discloses a public-private initiative to speed cancer vaccine development, modeled on the Covid-19 response. Details on funding, timeline, and specific targets remain unclear. This signals a major policy shift toward collaborative vaccine R&D, potentially impacting biotech valuations.